Evidence map›Paper›PMID 39893209›Full record

ArticleNature communications2025

Bidirectional relationship between epigenetic age and stroke, dementia, and late-life depression.

Cyprien A Rivier, Natalia Szejko, Daniela Renedo, Santiago Clocchiatti-Tuozzo, Shufan Huo, Adam de Havenon, Hongyu Zhao, Thomas M Gill, Kevin N Sheth, Guido J Falcone

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Cyprien A RivierDepartment of Neurology, Yale School of Medicine, New Haven, CT, US. Cyprien.rivier@yale.edu.ORCID http://orcid.org/0000-0002-1148-1829
Natalia SzejkoDepartment of Bioethics, Medical University of Warsaw, Warsaw, Poland.
Daniela RenedoDepartment of Neurology, Yale School of Medicine, New Haven, CT, US.
Santiago Clocchiatti-TuozzoDepartment of Neurology, Yale School of Medicine, New Haven, CT, US.
Shufan HuoDepartment of Neurology, Yale School of Medicine, New Haven, CT, US.
Adam de HavenonDepartment of Neurology, Yale School of Medicine, New Haven, CT, US.
Hongyu ZhaoDepartment of Biostatistics, Yale School of Public Health, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-1195-9607
Thomas M GillDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-6450-0368
Kevin N ShethDepartment of Neurology, Yale School of Medicine, New Haven, CT, US.ORCID http://orcid.org/0000-0003-2003-5473
Guido J FalconeDepartment of Neurology, Yale School of Medicine, New Haven, CT, US. guido.falcone@yale.edu.ORCID http://orcid.org/0000-0002-6407-0302

Funding

HRS Yrs29-34: Y33 SSA CoFundingU01AG009740 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jessica Faul, KENNETH M LANGA · 1990 to 2026
$555.8M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Study Support Suite (YES3): Dashboard and Web Portal Software Supporting Research Workflow through integrated, customizable REDCap External ModulesP30AG021342 · NIA · YALE UNIVERSITY · PI Lauren Ferrante · 2002 to 2026
$37.9M
Anticoagulation in ICH Survivors for Prevention and Recovery (ASPIRE)U01NS106513 · NINDS · YALE UNIVERSITY · PI Hooman Kamel, Kevin Navin Sheth · 2019 to 2026
$20.6M
Yale Training Program in Geriatric Clinical Epidemiology and Aging-Related ResearchT32AG019134 · NIA · YALE UNIVERSITY · PI Terri R. Fried · 2001 to 2026
$7.5M
CTP to predict Response to recanalization in Ischemic Stroke Project (CRISP)R01NS075209 · NINDS · STANFORD UNIVERSITY · PI LANSBERG, MAARTEN G · 2011 to 2023
$6.0M
Southern New England Partnership In Stroke Research, Innovation and Treatment (SPIRIT)U24NS107215 · NINDS · YALE UNIVERSITY · PI MARK Jay ALBERTS, Karen L Furie · 2018 to 2026
$3.0M
Blood Pressure Variability and Ischemic Stroke Outcome (BP-VISO)R01NS130189 · NINDS · YALE UNIVERSITY · PI Adam H. de Havenon · 2023 to 2026
$2.0M
CAPTIVA-MRIUG3NS130228 · NINDS · YALE UNIVERSITY · PI AMIN-HANJANI, SEPIDEH, CHATTERJEE, ARINDAM R. · 2023 to 2023
$1.9M
Improved glyburide therapy via acid- triggered release functional nanoparticles and therapeutic imagingR01NS110721 · NINDS · YALE UNIVERSITY · PI SHETH, KEVIN NAVIN, ZHOU, JIANGBING · 2019 to 2023
$1.9M
Yale Clinical Site: Investigations For Improved Neurological Treatments at Yale (INFINITY)U24NS107136 · NINDS · YALE UNIVERSITY · PI SHETH, KEVIN NAVIN, SPUDICH, SERENA S · 2018 to 2022
$1.7M
Yale site for Stroke Preclinical Assessment Network (SPAN) for Acute NeuroprotectionU01NS113445 · NINDS · YALE UNIVERSITY · PI SANSING, LAUREN H · 2019 to 2021
$1.2M
American Heart Association (American Heart Association, Inc.) 24RSSPOST1328228American Heart Association (American Heart Association, Inc.) 817874NCATS NIH HHS UL1 TR001863NIA NIH HHS P30 AG021342NIA NIH HHS T32 AG019134NIA NIH HHS U01 AG009740NINDS NIH HHS K23 NS105924NINDS NIH HHS R01 NS075209NINDS NIH HHS R01 NS110721NINDS NIH HHS R01 NS130189NINDS NIH HHS R03 NS112859NINDS NIH HHS U01 NS106513NINDS NIH HHS U01 NS113445NINDS NIH HHS U24 NS107136NINDS NIH HHS U24 NS107215NINDS NIH HHS UG3 NS130228
6 · The paper itself

Abstract

Chronological age is an imperfect estimate of molecular aging. Epigenetic age, derived from DNA methylation data, provides a more nuanced representation of aging-related biological processes. We examine the bidirectional relationship between epigenetic age and brain health events (stroke, dementia, late-life depression) using data from 4,018 participants. Participants with a prior brain health event are 4% epigenetically older (β = 0.04, SE = 0.01), indicating these conditions are associated with accelerated aging beyond that captured by chronological age. Additionally, a one standard deviation increase in epigenetic age is associated with 70% higher odds of experiencing a brain health event in the next four years (OR = 1.70, 95% CI = 1.16-2.50), suggesting epigenetic age acceleration is not just a consequence but also a predictor of poor brain health. Mendelian Randomization analyses replicate these findings, supporting their causal nature. Our results support using epigenetic age as a biomarker to evaluate interventions aimed at preventing and promoting recovery after brain health events.

Indexed as

AgingDementiaDepressionEpigenesis, GeneticStrokeAgedAged, 80 and overBrainDNA MethylationFemaleHumansMaleMendelian Randomization AnalysisMiddle Aged

Identifiers

PMID39893209
PMCPMC11787333

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.